First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients

This is a first-in-human study testing a new drug called ABD-3001 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) — both serious blood cancers that have not responded to other treatments. The study focuses on safety, how the drug behaves in the body, and early signs of whether it works. **You may be eligible if...** - You have AML that has come back or stopped responding after at least one standard treatment - You have high-risk or very high-risk MDS that is no longer responding to treatment and you are not eligible for other salvage therapies - Your general health and organ function meet the required levels **You may NOT be eligible if...** - You have active brain involvement from your blood cancer - You have had a bone marrow transplant recently and still have transplant-related complications - You have serious infections or other serious health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.